Sign up for a new account.
And get access to
The latest T1D content
Research that matters
Our daily questions
Sign up by entering your info below.
Reset Your Password
We will email you instructions to reset your
About the study
If you’re 16 years or older and were diagnosed with type 1 diabetes within the past 12 months, you may qualify for a new clinical study at Joslin Diabetes Center in Boston.
Type 1 diabetes is a serious condition in which the pancreas stops producing insulin. Many people with type 1 diabetes have a problem with how certain immune cells function – and it’s believed these malfunctioning immune cells contribute to the development of type 1 diabetes.
Doctors at Joslin Diabetes Center in Boston are evaluating an investigational treatment for diabetes, called AVT001. This treatment is made from a person’s own cells.
Researchers believe AVT001 may help correct the underlying immune condition in people with type 1 diabetes, thereby helping the body naturally produce insulin.
If you qualify and choose to join the study, you will receive all study-related care at no cost from a specialist at Joslin Diabetes Center.
Doctors at Joslin Diabetes Center are evaluating an investigational treatment for diabetes, called AVTOO. If you are 16 years or older and were diagnosed with type 1 diabetes within the past 12 months, you may be eligible to participate. If you qualify and choose to join the study, you will receive:
- Evaluations of your type 1 diabetes from a specialist at Joslin Diabetes Center
- All study-related care at no cost
- Compensation for your time and travel to attend study visits.
- Additional travel funds may be available on a case-by-case basis.
- The opportunity to help advance type 1 diabetes research to possibly benefit others with type 1 diabetes.
Are you eligible?
To see if you might qualify for the study, and to get connected with a research specialist at Joslin Diabetes Center to discuss the study further, please click here.
This site uses Akismet to reduce spam. Learn how your comment data is processed.
Join our mailing list for more about T1D
- Dr. Osagie Ebekozien Awarded ISPAD’s Prize for Innovation in Pediatric Diabetes Careby Sarah TackettOctober 13, 2021
- T1D Exchange Research Highlights from ISPAD 2021by Sarah TackettOctober 13, 2021
- Status Update: Connected Insulin Delivery Devicesby Hope WarshawOctober 7, 2021
- Top Questions of the Day – September 2021by Sarah TackettSeptember 30, 2021
- Connect1d Canada partners with the T1D Exchangeby Deborah TaylorSeptember 20, 2021